Literature DB >> 25342618

A comparison of progressive loss of the ellipsoid zone (EZ) band in autosomal dominant and x-linked retinitis pigmentosa.

Cindy X Cai1, Kirsten G Locke2, Rithambara Ramachandran3, David G Birch4, Donald C Hood5.   

Abstract

PURPOSE: In patients with retinitis pigmentosa (RP), the inner segment ellipsoid zone (EZ; also known as the inner segment/outer segment [IS/OS] border) is a marker of the usable visual field at a given point in time and of the progression of the disease over time. Here we compare the change in the width per year of the EZ band in patients with autosomal dominant (ad) and x-linked (xl) RP.
METHODS: Using optical coherence tomography (OCT), 9-mm horizontal and vertical line scans through the fovea were obtained for one eye of 26 xlRP patients and 33 adRP patients. Scans were repeated on average 2.0 years later (range, 0.6-4.8 years). Using a manual segmentation procedure, the EZ band was delineated and its horizontal width (HW) and vertical width (VW) were determined.
RESULTS: The adRP and xlRP patients had similar initial EZ HW (xlRP: 11.8 ± 5.4°, adRP: 12.4 ± 6.3°, P = 0.69) and VW (xlRP: 8.5 ± 4.9°, adRP: 11.4 ± 7.1°, P = 0.09). However, between visits the absolute loss and percent loss of the EZ width per year was significantly greater for xlRP than adRP for both HW (xlRP: 1.0 ± 0.6°/y, 9.6 ± 5.6%/y; adRP: 0.4 ± 0.5°/y, 3.4 ± 5.4%/y; P < 0.001) and VW (xlRP: 0.8 ± 0.8°/y, 9.2 ± 8.9%/y; adRP: 0.3 ± 0.5°/y, 4.2 ± 6.4%/y; P < 0.01). There was a weak correlation between the loss of EZ width per year and the initial width for xlRP (r(2) = 0.17, P = 0.036), but no correlation for adRP (r(2) = 0.004, P = 0.73). The test-retest difference of EZ HW was 0.2 ± 0.5°.
CONCLUSIONS: The OCT data here support a faster rate of loss per year in the case of xlRP. (ClinicalTrials.gov number, NCT00100230.). Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  optical coherence tomography; progression; retinitis pigmentosa

Mesh:

Substances:

Year:  2014        PMID: 25342618      PMCID: PMC4238317          DOI: 10.1167/iovs.14-15013

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  The transition zone between healthy and diseased retina in patients with retinitis pigmentosa.

Authors:  Donald C Hood; Margot A Lazow; Kirsten G Locke; Vivienne C Greenstein; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

Review 2.  Retinitis pigmentosa.

Authors:  Dyonne T Hartong; Eliot L Berson; Thaddeus P Dryja
Journal:  Lancet       Date:  2006-11-18       Impact factor: 79.321

3.  Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa.

Authors:  David G Birch; Kirsten G Locke; Yuquan Wen; Kelly I Locke; Dennis R Hoffman; Donald C Hood
Journal:  JAMA Ophthalmol       Date:  2013-09       Impact factor: 7.389

4.  A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa.

Authors:  Nalini V Rangaswamy; Hemaxi M Patel; Kirsten G Locke; Donald C Hood; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-10       Impact factor: 4.799

5.  Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations.

Authors:  Michael A Sandberg; Bernard Rosner; Carol Weigel-DiFranco; Thaddeus P Dryja; Eliot L Berson
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

6.  Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.

Authors:  Dennis R Hoffman; Dianna K Hughbanks-Wheaton; N Shirlene Pearson; Gary E Fish; Rand Spencer; Alison Takacs; Martin Klein; Kirsten G Locke; David G Birch
Journal:  JAMA Ophthalmol       Date:  2014-07       Impact factor: 7.389

7.  Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy.

Authors:  D G Birch; J L Anderson; G E Fish
Journal:  Ophthalmology       Date:  1999-02       Impact factor: 12.079

8.  Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography.

Authors:  Donald C Hood; Christine E Lin; Margot A Lazow; Kirsten G Locke; Xian Zhang; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-14       Impact factor: 4.799

9.  Method for deriving visual field boundaries from OCT scans of patients with retinitis pigmentosa.

Authors:  Donald C Hood; Rithambara Ramachandran; Karen Holopigian; Margot Lazow; David G Birch; Vivienne C Greenstein
Journal:  Biomed Opt Express       Date:  2011-04-05       Impact factor: 3.732

10.  A Comparison of Methods for Tracking Progression in X-Linked Retinitis Pigmentosa Using Frequency Domain OCT.

Authors:  Rithambara Ramachandran; Lisa Zhou; Kirsten G Locke; David G Birch; Donald C Hood
Journal:  Transl Vis Sci Technol       Date:  2013-11-11       Impact factor: 3.283

View more
  45 in total

1.  Two-Step Reactivation of Dormant Cones in Retinitis Pigmentosa.

Authors:  Wei Wang; Sang Joon Lee; Patrick A Scott; Xiaoqin Lu; Douglas Emery; Yongqin Liu; Toshihiko Ezashi; Michael R Roberts; Jason W Ross; Henry J Kaplan; Douglas C Dean
Journal:  Cell Rep       Date:  2016-03-31       Impact factor: 9.423

2.  Time Course of Disease Progression of PRPF31-mediated Retinitis Pigmentosa.

Authors:  Kelly Kiser; Kaylie D Webb-Jones; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; David G Birch
Journal:  Am J Ophthalmol       Date:  2018-12-21       Impact factor: 5.258

3.  Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.

Authors:  Peter A Campochiaro; Mustafa Iftikhar; Gulnar Hafiz; Anam Akhlaq; Grace Tsai; Dagmar Wehling; Lili Lu; G Michael Wall; Mandeep S Singh; Xiangrong Kong
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa.

Authors:  Ruben Jauregui; Karen Sophia Park; Jimmy K Duong; Janet R Sparrow; Stephen H Tsang
Journal:  Am J Ophthalmol       Date:  2018-07-24       Impact factor: 5.258

5.  Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.

Authors:  David G Birch; Paul S Bernstein; Alessandro Iannacone; Mark E Pennesi; Byron L Lam; John Heckenlively; Karl Csaky; Mary Elizabeth Hartnett; Kevin L Winthrop; Thiran Jayasundera; Dianna K Hughbanks-Wheaton; Judith Warner; Paul Yang; Gary Edd Fish; Michael P Teske; Neal L Sklaver; Laura Erker; Elvira Chegarnov; Travis Smith; Aimee Wahle; Paul C VanVeldhuisen; Jennifer McCormack; Robert Lindblad; Steven Bramer; Stephen Rose; Patricia Zilliox; Peter J Francis; Richard G Weleber
Journal:  JAMA Ophthalmol       Date:  2018-08-01       Impact factor: 7.389

6.  Variegated yet non-random rod and cone photoreceptor disease patterns in RPGR-ORF15-associated retinal degeneration.

Authors:  Jason Charng; Artur V Cideciyan; Samuel G Jacobson; Alexander Sumaroka; Sharon B Schwartz; Malgorzata Swider; Alejandro J Roman; Rebecca Sheplock; Manisha Anand; Marc C Peden; Hemant Khanna; Elise Heon; Alan F Wright; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

7.  Clinical trial design for neuroprotection in RHO autosomal dominant retinitis pigmentosa; outcome measure considerations.

Authors:  Benjamin Otte; Chris Andrews; Gabrielle Lacy; Kari Branham; David C Musch; Kanishka T Jayasundera
Journal:  Ophthalmic Genet       Date:  2021-01-06       Impact factor: 1.803

8.  Defining inclusion criteria and endpoints for clinical trials: a prospective cross-sectional study in CRB1-associated retinal dystrophies.

Authors:  Mays Talib; Mary J van Schooneveld; Jan Wijnholds; Maria M van Genderen; Nicoline E Schalij-Delfos; Herman E Talsma; Ralph J Florijn; Jacoline B Ten Brink; Frans P M Cremers; Alberta A H J Thiadens; L Ingeborgh van den Born; Carel B Hoyng; Magda A Meester-Smoor; Arthur A Bergen; Camiel J F Boon
Journal:  Acta Ophthalmol       Date:  2021-02-02       Impact factor: 3.761

9.  Spectrum of Disease Severity in Nonsyndromic Patients With Mutations in the CEP290 Gene: A Multicentric Longitudinal Study.

Authors:  Francesco Testa; Andrea Sodi; Sabrina Signorini; Valentina Di Iorio; Vittoria Murro; Raffaella Brunetti-Pierri; Enza Maria Valente; Marianthi Karali; Paolo Melillo; Sandro Banfi; Francesca Simonelli
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-07-01       Impact factor: 4.799

10.  Monitoring progression of retinitis pigmentosa: current recommendations and recent advances.

Authors:  Moreno Menghini; Jasmina Cehajic-Kapetanovic; Robert E MacLaren
Journal:  Expert Opin Orphan Drugs       Date:  2020-03-02       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.